1. Home
  2. FNWD vs IMUX Comparison

FNWD vs IMUX Comparison

Compare FNWD & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

SELL

Current Price

$41.24

Market Cap

187.1M

Sector

Finance

ML Signal

SELL

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$8.02

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
IMUX
Founded
1994
2016
Country
United States
United States
Employees
N/A
66
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.1M
155.8M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
FNWD
IMUX
Price
$41.24
$8.02
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $43.09
AVG Volume (30 Days)
7.8K
★ 405.8K
Earning Date
10-29-2026
11-12-2026
Dividend Yield
★ 1.17%
N/A
EPS Growth
N/A
★ 38.00
EPS
★ 1.00
N/A
Revenue
N/A
N/A
Revenue This Year
$10.81
N/A
Revenue Next Year
$5.26
N/A
P/E Ratio
$41.24
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.05
$0.51
52 Week High
$45.90
$17.43

Technical Indicators

Market Signals
Indicator
FNWD
IMUX
Relative Strength Index (RSI) 44.01 29.56
Support Level $41.49 $0.83
Resistance Level $44.01 $15.82
Average True Range (ATR) 0.63 0.67
MACD -0.08 0.05
Stochastic Oscillator 24.86 18.10

Price Performance

Historical Comparison
FNWD
IMUX

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: